ArticleFrontiers in medicine2026
Integrated transcriptomic and immune analysis reveals distinct mitochondrial and immune signature in COVID-19 ARDS requiring invasive mechanical ventilation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe COVID-19-related acute respiratory distress syndrome (ARDS) often progresses to respiratory failure requiring invasive mechanical ventilation (IMV). Although several biomarkers (e.g., CRP, suPAR, Ang-2) have been explored to predict COVID-19 disease severity, validated early-presentation biomarkers that specifically prognosticate the need for IMV and mechanistic pathways in ARDS remain limited. Research question: What transcriptomic and immune signatures distinguish IMV from non-IMV in patients with COVID-19 ARDS, and how do these molecular changes contribute to disease severity? Methods: Patients ( Results: Clinically, IMV patients had significantly longer hospital (43.0 vs. 19.5 days, Conclusion: Patients requiring IMV demonstrated distinct transcriptomic and immune profiles associated with severe COVID-19. These findings identify candidate biomarkers and pathways associated with disease severity; however, the results are exploratory and require validation in larger cohorts and functional studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.